Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 81.3% in March

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 78,484 shares, a decline of 81.3% from the March 15th total of 419,845 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 845,596 shares, the days-to-cover ratio is presently 0.1 days.

Daiichi Sankyo Price Performance

Shares of OTCMKTS:DSNKY opened at $17.57 on Monday. The stock has a fifty day simple moving average of $18.51 and a two-hundred day simple moving average of $21.41. The stock has a market capitalization of $33.28 billion, a price-to-earnings ratio of 16.12, a PEG ratio of 0.91 and a beta of -0.04. Daiichi Sankyo has a 12-month low of $17.44 and a 12-month high of $28.21. The company has a current ratio of 2.69, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.05. The business had revenue of $3.65 billion during the quarter, compared to analysts’ expectations of $3.88 billion. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%. On average, research analysts anticipate that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.